Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Interest Income

Income earned on cash, deposits, and investments held by the company.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Interest Income · Q2 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q2 FY2026 interest income was $3, compared with $0 a year earlier. Trailing-twelve-month interest income was $3.

Context

  • Interest income amounted to 6.3% of revenue in FY2025.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly interest income holds near $3 or moves back toward the trailing-twelve-month quarterly average of $0.75.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3— QoQ
Last fiscal yearSep 2025
$89.74K-90.1% YoY
LTMMar 2026
$3-100.0% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-90.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
89.74K USD
Year-over-year change
-90.1%

Interest Income vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 interest income of $3 is the lowest of the 9 companies compared; the peer median is $863K.
  • Its year-over-year change of -100.0% is the lowest of 8, against a peer median of -38.5%.
  • Interest income amounts to 0.0% of revenue for OTLK, versus a peer median of 5.3%.
OTLK Competitors Peer median
Interest Income for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$6.94M -43.0%+34.9%—
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$1.97M -58.5%+17.7%9.4%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$1.18M -58.1%-9.3%—
EQEquillium, Inc.LTM Mar 2026$969K -13.0%+25.6%—
CUECue Biopharma, Inc.LTM Mar 2026$757K -38.5%-4.6%2.3%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$116.5K ——8.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$13K -38.1%-63.6%0.6%
OSTXOS Therapies IncorporatedLTM Mar 2026$228 +245.5%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3 -100.0%—0.0%
Peer median (excluding OTLK) $863K-38.5%+6.6%5.3%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.